«To preserve patient access to this treatment option, and given the scale that we've reached, demonstrating the safety and efficacy of
fecal transplantation through adequate and well - controlled clinical trials is the right thing to do,» explained Carolyn Edelstein, OpenBiome's director of Outreach and Public Affairs, in an op - ed published earlier today with the Fecal Transplant Foundation.
«
Through it, we will provide safe access to
fecal transplantation for patients with recurrent C. difficile today, and help Finch pursue FDA approval so that patients have this access in perpetuity.